(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 26.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Vericel's revenue in 2024 is $197,516,000.On average, 3 Wall Street analysts forecast VCEL's revenue for 2024 to be $11,608,134,493, with the lowest VCEL revenue forecast at $11,593,502,573, and the highest VCEL revenue forecast at $11,615,716,049. On average, 3 Wall Street analysts forecast VCEL's revenue for 2025 to be $14,934,360,989, with the lowest VCEL revenue forecast at $14,425,720,692, and the highest VCEL revenue forecast at $15,358,203,759.
In 2026, VCEL is forecast to generate $19,564,518,494 in revenue, with the lowest revenue forecast at $19,076,063,485 and the highest revenue forecast at $20,052,973,503.